NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Picot J, Cooper K, Bryant J, et al. The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Dec. (Health Technology Assessment, No. 15.41.)

Cover of The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation

The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation.

Show details

Appendix 9Table of excluded studies for systematic review of health-related quality of life

Excluded referenceReason for exclusion
Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 2009;15:12–20Outcome
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008;143:511–19Participants and outcome
Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 2004;33:955–62Outcome
Gulbrandsen N, Wisloff F, Brinch L, Carlson K, Dahl IM, Gimsing P, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65–77Participants and outcome
Multiple myeloma: QALY gains from optimal therapy. Drugs Ther Perspect 2000;16:12–16Outcome
Ellis K, Smith AG. An evaluation of quality of life (QOL) in patients after treatment for multiple myeloma (MM). Br J Haematol 2005;129:192Outcome
Thomas ML. Quality of life in persons with multiple myeloma: a descriptive study. Blood 2001;98:4971Outcome
Deniz B, Morgan G, Schey S, Ishak J, Dale P, Shearer A et al. Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK. Blood 2008;112:836–7Outcome
Belch A, Reece DE, Bahlis NJ, White D, Teixeira B, Camacho F, et al. Bortezomib [VELCADE (TM)], pegylated liposomal doxorubicin [DOXIL/CAELYX (R)] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-life. Blood 2007;110:A1058–9Outcome
Petrucci MT, Calabrese E, Levi A, Federico V, Ceccolini M, Rizzi D, et al. Costs and quality of life of multiple myeloma (MM) in Italy: the Co. Mim Study. Value Health 2009;12:A265Abstract
Meunier J, Regnault A, Robinson D, Rosa K, Miguel JFS, van de Velde H, et al. Impact of tumor response on health-related quality of life (HRQOL) in newly diagnosed multiple myeloma patients treated with velcade/melphalan/prednisone (V-MP): results from the Vista Trial. Value Health 2009;12:A284Abstract
Dhawan R, Meunier J, Regnault A, Robinson D, Rosa K, Cakana A, et al. Impact of complete response on quality of life in newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma 2009;9:S58Abstract
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK97475

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.5M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...